Introduction {#sec1-1}
============

In 1999, WHO stated that gestation diabetes mellitus (GDM) encompass from impaired glucose tolerance to diabetes (fasting ≥7 mmol/l or ≥126 mg/dl; 2 h plasma glucose ≥7.8 mmol/l or 140 mg/dl) and this position has been maintained over the years ([@r1]).

More recently, the International Association of the Diabetes in Pregnancy Study Group (IADPSG), after extensive analyses of the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, recommended new diagnostic criteria for GDM based on the 2 h, 75 g OGTT: a fasting glucose ≥5.1 mmol/L (92 mg/dl), or a one hour result of ≥10.0 mmol/L (180 mg/dL), or a two hour result of ≥8.5 mmol/L (153 mg/dL) ([@r2], [@r3]).

The purpose of this study is to report the association of diabetes mellitus (DM) and GDM, as diagnosed by the IADPSG criteria, with different pregnancy outcomes, in treated women with GDM and in women with pre-existing DM in Qatar. In addition, our results are compared with other large cohort studies published in different countries.

Patient and Methods {#sec1-2}
===================

Data were derived from Qatar Perinatal Registry, developed in 2011, and reactivated in 2016 as Qatar PEARL-Peristat Registry. It was funded by Qatar National Research Fund (QNRF) and sponsored by the Medical Research Center (MRC) of Hamad Medical Corporation, Doha (Qatar). The registry contains abstracted data of routinely collected hospital data from all hospitals with delivery facilities in Qatar, spanning the perinatal to postpartum periods. By utilizing patient care records, the registry aims to examine the short and long-term maternal and newborn health outcomes. In addition, the study aims to explore the development of specified sub-cohorts with intent of improving reproductive health outcomes of the Qatar population. The registry houses delivery cohorts from 2011 to 2012, as the first phase, and currently 2017 to 2019, as a second phase, with the current phase targeting around 35,000 deliveries within the whole country. Data collection for the current phase is still ongoing.

For the current study, data for women with singleton births and completed record abstraction, between January - August 2017, were analyzed. 12,255 singleton pregnant women were identified of which, 3,027 women were identified with GDM and 233 with DM before pregnancy, according to the criteria of the International Association of the Diabetes in Pregnancy Study Group (IADPSG) ([@r4]).

Management of diabetes during pregnancy {#sec1-3}
=======================================

All pregnant women with dysglycemia were managed by multi-disciplinary care teams, including 2-3 examinations by diabetologists during pregnancy. Women enrolled in outpatient GDM management received one-on-one education/counseling and individualized GDM plan of care designed by certified diabetes educators (CDE). Education and counseling provided by the CDE included information on blood glucose testing, diabetes diet, exercise, and self-care activities. Every patient had a glucometer at home and was advised to do self -monitoring of blood glucose. Patients with multi-doses injections of insulin were advised to monitor the glucose levels 6-7 times per day (fasting blood glucose, pre-meals, 2 hours after meals and before bedtime). Patients on metformin or single dose of basal insulin were advised to monitor the glucose levels 4 times per day (fasting before meals, and before bedtime). The target blood sugar levels were as follows: a fasting blood glucose ≤5.3 mmol/l (≤95 mg/dL) and 2 hours after meals ≤6.7 mmol/l (≤120 mg/dL) without hypoglycemia. Patients on insulin treatment were advised to keep their capillary blood glucose above 4 mmol/l (72 mg/dL) and to monitor hemoglobin A1c (HBA1c). Hb A1c was measured in the first clinic visit and at least once in each trimester with a target HbA1c = ≤6.5%.

Variables {#sec1-4}
=========

The following maternal data were included: maternal age at delivery, parity, nationality, body mass index (BMI), duration of gestation, mode of delivery, induction of labor, hypertensive disorders in pregnancy and any adverse effects on the mother. Neonatal data included: birth weight, gestational age, birth status (live born/stillborn), gender, preterm, macrosomia, admission to neonatal intensive care unit, blood glucose status, bilirubin status, phototherapy treatment, respiratory status, neonatal death and congenital anomalies.

Hypertension that was present before 20 weeks gestation and did not progress to preeclampsia was classified as chronic hypertension. Hypertensive disorders occurring after 20 weeks were categorized according to the International Society for the Study of Hypertension guidelines. Preeclampsia was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mm Hg on two or more occasions at least 6 h apart and proteinuria ≥1 + on dipstick or ≥300 mg to 24-h urine collection. If the criteria for elevated blood pressure were met without proteinuria, this was classified as gestational hypertension ([@r5]).

Preterm delivery was defined as delivery prior to 37 weeks gestation. Macrosomia was defined as birth weight ≥4 kilogram. Clinical neonatal hypoglycemia was defined by one or more clinical criteria: the presence of neonatal hypoglycemia registered in the medical record and symptoms or treatment with a glucose infusion or a laboratory-reported glucose value ≤1.7 mmol/L in the first 24 h after birth or ≤2.5 mmol/L after the first 24 h ([@r6]).

Results {#sec1-5}
=======

The prevalence of GDM and DM was 24.7% and 1.9%, respectively ([Table 1](#T1){ref-type="table"}). Seventy-one percent of pregnant women with DM and 57.8% of those with GDM were older than 30 years versus 44.2% of those with normal glycemia ([Figure 1A](#F1){ref-type="fig"}). Fifty-five percent of DM, 38% of GDM and 25.6% of controls were obese (p\<0.001) ([Figure 1B](#F1){ref-type="fig"}). Pregnant women with DM and GDM had higher prevalence of hypertension versus normal controls (9.9%, 5.5 % and 3.5%, respectively; p\<0.001). Among women with vaginal deliveries, the proportion of women who underwent induction of labor was significantly higher in DM and GDM subjects compared to controls (33.9%, 26.5% and 12.4%, respectively; p\<0.001). The number of women who underwent Cesarean section was significantly higher in the DM and GDM groups versus normal controls (51.9%, 36.8%, and 28.5%, respectively; p\<0.001) ([Table 1](#T1){ref-type="table"} and [Figure 1C](#F1){ref-type="fig"}).

###### 

Maternal and neonatal demographics

![](ACTA-89-11-g001)

![A: Maternal age distribution in the different groups (DM, GDM, normal (No DM) and total; B: Pre-gestation BMI in the different groups (DM, GDM, normal (No DM) and total; C: Mode of delivery in in the different groups (DM, GDM, Normal (No DM) and total; D: Prevalence of premature labor in the different groups (DM, GDM, normal (No DM) and total; E: Prevalence of macrosomia in newborns of the different groups (DM, GDM, normal (No DM) and total; F: Prevalence of hypoglycemia in the newborns of the different groups (DM, GDM, normal (No DM).](ACTA-89-11-g002){#F1}

Babies of DM and GDM women required more frequent admission to Neonatal Intensive Care unit (NICU) (25% and 16%, respectively) versus control babies (12%) (p: \<0.001). Preterm delivery was significantly higher in women with DM and GDM (13.7% and 9%, respectively) versus normal women (6.4%) (p: \<0.001) ([Figure 1D](#F1){ref-type="fig"}). Macrosomia was more prevalent in babies of DM (6.4%) and GDM (6.8%) women compared to controls (5%) (p: \<0.001) ([Table 2](#T2){ref-type="table"} and [Figure 1D](#F1){ref-type="fig"}).

###### 

Neonatal outcomes within groups

![](ACTA-89-11-g003)

Significant hypoglycemic episodes occurred more frequently in babies of DM and GDM women (11.2%, and 3%, respectively) versus controls (0.6%) (p: \<0.001) ([Figure 1F](#F1){ref-type="fig"}). Babies of DM and GDM mothers required more phototherapy (9.4%% and 8.9%, respectively) versus those of non-diabetic women (7.2%) (p: 0.006).

The prevalence of neonatal death and congenital anomalies did not differ significantly between the babies of DM and GDM mothers and babies of non-diabetic women ([Table 2](#T2){ref-type="table"}).

Discussion {#sec1-6}
==========

Gestational diabetes mellitus (GDM) is a heterogeneous disorder that is defined as carbohydrate intolerance with first recognition during pregnancy. GDM is a common medical problem that results from an increase in the insulin resistance as well as an impairment of the compensatory increase in insulin secretion from the β-cells of the pancreas. GDM is linked with a variety of maternal and fetal complications, most notably macrosomia, prematurity, neonatal hypoglycemia, respiratory distress, and more admission to NICU. Controlling maternal blood sugar with medical nutrition therapy, close monitoring of blood glucose levels and treatment with insulin to control blood glucose has been shown to decrease fetal and maternal morbidities.

GDM is a result of the interaction between genetic and environmental risk factors. Increased body fat and high caloric diet contribute to the risk of GDM; patients who lose weight before pregnancy and follow an appropriate diet may lower the GDM risks ([@r7]-[@r9]).

The reported prevalence of GDM varies widely from 1% to 14% of all pregnancies. Our cohort consisted of 25% Qatari and 75 % non-Qatari women. Data showed a high prevalence of GDM compared to most of the published studies in different countries using the criteria of the International Association of the Diabetes in Pregnancy Study Group (IADPSG) for diagnosing GDM ([Table 3](#T3){ref-type="table"}) ([@r10]-[@r21]).

###### 

Main characteristics of previous published studies (Ref. 12-23) in comparison to our study
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This can be explained in part by the high prevalence of obesity and overweight in our cohort compared to others. Fifty-five percent of our patients who suffered from DM, 38% from GDM and 25.6% from controls were obese. A review and a meta-analysis by Torloni et al. ([@r12]) revealed that the relative risks for developing GDM (RR) measured for overweight, moderately obese and morbidly obese women (pre-pregnancy BMI) were 1.97 (95% CI 1.77 to 2.19), 3.01 (95% CI 2.34 to 3.87) and 5.55 (95% CI 4.27 to 7.21), respectively. For every 1 kg/m^2^ increase in BMI, the prevalence of GDM increased by 0.92% (95% CI 0.73 to 1.10). The risk of GDM was positively associated with pre-pregnancy BMI. In addition, it appeared that genetic background and other environmental factors were additional risk factors for developing GDM in Qatar.

A cross-sectional analysis of 3,017 Qatari subjects from the Qatar Biobank, identified 749 women, aged 18-40 years, 720 of whom were assessed. Prediabetes \[HbA1c: 5.7-6.4 % and/or impaired fasting glucose (IFG: 100-125 mg/dL; 5.6-6.9 mmol/L), and T2DM (fasting plasma glucose \>125 mg/dL; ≥7 mmol/L), and/or HbA1c ≥6.5%\] were determined. The prevalence of prediabetes was 10.6%, and the prevalence of DM was found to be 4.0% of the total population. Obesity appeared to be an important risk factor for the development of DM. (BMI ≥30, adjusted OR = 2.2; 95% CI = 1.5-3.2; p\<0.0001) ([@r22], [@r23]).

The relative incidence (RR) of preeclampsia, perinatal mortality, macrosomia, Caesarean section, among women with and without gestational diabetes were compared to large cohorts of subjects published in the literature ([Table 4](#T4){ref-type="table"}) ([@r24]-[@r26]). Neonatal Complications of GDM in our study were different compared to other studies with larger cohort ([Table 5](#T5){ref-type="table"}) ([@r27]-[@r31]). Macrosomia and/or large for gestational age (LGA) was the predominant adverse outcome associated with maternal hyperglycemia. In addition, macrosomia was the main reason underlying birth trauma and preterm birth, difficult labor and cesarean delivery. Treatment of GDM is supposed to decrease the risk of fetal macrosomia ([@r32]-[@r36]). Although macrosomia occurred more frequently in the babies of GDM versus control mothers, the prevalence of macrosomia in our cohort was lower than those reported by many other studies ([Table 4](#T4){ref-type="table"}). This may be due to the proper use of the timed Caesarean section in our dysglycemic women, which relatively increased the prevalence of Caesarean section with no increase in the neonatal mortality compared to control mothers.

###### 

Relative incidence (RR) of pre-eclampsia, perinatal mortality, macrosomia, and Cesarean section, among women with and without gestational diabetes (Ref. 29-31)
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###### 

Neonatal complications of GDM in different studies (Ref. 32-37)
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In the HAPO study ([@r17]), there were significantly greater odds of birth weight, newborn percent body fat and cord C-peptide \>90th percentile, primary cesarean delivery, and preeclampsia for GDM or obesity alone compared with the reference group. The combination of GDM and obesity showed substantially higher ORs compared with those for either GDM or obesity alone. Shoulder dystocia or birth injury was uncommon (1.3% overall), and odds for these outcomes were significantly greater compared to reference group only when GDM and obesity were both present ([@r29]).

The risk for developing hypoglycemia among infants of diabetic mothers is higher than in non-diabetic mothers. Hypoglycemia occurs in approximately 8-30% of neonates of mothers with diabetes, with an estimated incidence rate of approximately 27% among infants of women with diabetes compared to 3% of healthy full-term infants of non-diabetic women. The full extent of the individual and contextual risk factors of hypoglycemia remains unclear. Both macrosomia and prematurity were suggested to contribute to the etiology of hypoglycemia in DM. The prevalence of hypoglycemia in babies of our GDM women was 3 %, relatively lower compared to other studies. Our results also showed a prevalence of hypoglycemia (2.7 %) in macrosomia infants versus non-macrosomia infants (1.3%).

In our cohort, the prevalence of hypoglycemia was significantly higher in preterm infants (4.5%) compared to full-term infants (1.1%). In the HAPO study ([@r17]), there were no significant differences between the glucose determinations and A1c for the associations with clinical neonatal hypoglycemia. A1c showed a stronger association to FPG for preterm delivery (p: 0.003) but no difference compared with 1- or 2-h PG. Although the odds of clinical neonatal hypoglycemia rose through the first six categories of A1c, there was no independent association of A1c with birth weight \>90th percentile or clinical neonatal hypoglycemia ([@r30]-[@r31]).

Comparing our neonatal outcome with those reported by Gonzalez et al. ([@r32]) on 3,218 women, we found that newborns of GDM women had a lower prevalence of hypoglycemia compared to the newborns of women with controlled GDM. This can be explained by our potent screening and management of pregnant women with GDM despite the proportionately high prevalence of GDM in our country ([@r33]-[@r37]).

Hypoglycemia occured in approximately 8-30% of neonates of mothers with diabetes. The full extent of the individual and contextual risk factors of hypoglycemia remains unclear.

In a total of 16 eligible published research articles, the clinical risk was broadly classified into: infant-related and mother-related risk factors. The identified infant-related risk factors were: SGA, macrosomia, prematurity, lower cord blood glucose, ponderal index and male sex. On the other hand, mother-related risk factors included maternal hyperglycemia, ethnic origin, diabetes diagnosed prior to 28 weeks of gestation, pre-pregnancy BMI≥25 kg/m^2^, blood glucose, maternal diabetes type and maternal HbA1c. Irrespective of diabetes type, infants of diabetic mothers appear to have a higher risk for developing hypoglycemia compared to control mothers ([@r38]).

Flores-le Roux et al. ([@r39]) prospectively examined the glucose levels in infants of women with GDM and the influence of maternal, gestational and peripartum factors on the development of hypoglycemia. They found that hypoglycemic infants were more frequently LGA (29.3% vs. 11.3%). Our data showed that hypoglycemia requiring NICU admission was more common in babies of DM (11.2%) and GDM (3%) compared to macrocosmic infants of control mothers (1.6%).

Garcia-Patterson et al. ([@r40]), using databases from a tertiary care center, examined the relationship between maternal pre-pregnancy BMI and hypoglycemia among infants of women with GDM and a gestational age above 22 weeks of gestation. The rate of neonatal hypoglycemia was 3%. Maternal pre-pregnancy BMI ≥25 kg/m^2^ was determined as an independent predictor of hypoglycemia ([@r41]-[@r43]). Our study showed that 72.5% of mothers with GDM and 87.8% of mothers with DM had a BMI\>25.

A summary of the world literature (1930-1964) on malformations in infants of diabetic mothers showed that the number of malformation was 4.8% compared to 1.65% of controls ([@r44]).

In our study, congenital malformation occurred in 1.3% and 1.1% of newborns of diabetic mothers and GDM mothers, respectively, and was not different than those from the normal controls (0.9%). In support of these data, malformation rates in infants of gestational diabetic women have been published by many centers and there is general agreement that malformation rates are not increased. Furthermore, the Collaborative Perinatal Project ([@r42]) showed that the malformation rates were 15.3% for whites and 13.7% for blacks. The corresponding rates for nondiabetics were 14.6 and 17.0%, respectively. The differences were not significant. This study clearly demonstrates that those without diabetes prior to pregnancy are not at increased risk for having malformed infants.

In conclusion {#sec1-7}
=============

Improvement in the diagnosis and management of pregnant women with dysglycemia lead to marked improvement in the neonatal outcome with a reduction in the rate of macrosomia, hypoglycemia, NICU admission and congenital malformations. However, there is still a higher prevalence of these comorbidities in infants of DM and GDM compared to normal women. Obesity and overweight in women during the childbearing period appears to contribute to the occurrence of high rates of dysglycemia during pregnancy. Measurements to reduce obesity during the childbearing period and control accurate glucose control during pregnancy are highly required to prevent any morbidity during pregnancy of women with DM and GDM.
